ATE465408T1 - Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins - Google Patents
Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxinsInfo
- Publication number
- ATE465408T1 ATE465408T1 AT04705647T AT04705647T ATE465408T1 AT E465408 T1 ATE465408 T1 AT E465408T1 AT 04705647 T AT04705647 T AT 04705647T AT 04705647 T AT04705647 T AT 04705647T AT E465408 T1 ATE465408 T1 AT E465408T1
- Authority
- AT
- Austria
- Prior art keywords
- encephalotoxin
- diagnosing
- detecting
- neurological diseases
- disclosed
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44321903P | 2003-01-27 | 2003-01-27 | |
| PCT/US2004/002236 WO2004066943A2 (en) | 2003-01-27 | 2004-01-27 | Methods for diagnosis anf monitoring of neurological disease by detection of an encephalotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465408T1 true ATE465408T1 (de) | 2010-05-15 |
Family
ID=32825308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04705647T ATE465408T1 (de) | 2003-01-27 | 2004-01-27 | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060035929A1 (de) |
| EP (2) | EP1592388B1 (de) |
| JP (2) | JP4571619B2 (de) |
| KR (2) | KR20050119104A (de) |
| CN (2) | CN100502847C (de) |
| AT (1) | ATE465408T1 (de) |
| AU (3) | AU2004207551B2 (de) |
| CA (2) | CA2514396A1 (de) |
| DE (1) | DE602004026683D1 (de) |
| IL (1) | IL169889A (de) |
| WO (2) | WO2004066943A2 (de) |
| ZA (2) | ZA200506033B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344853B2 (en) | 2003-01-27 | 2008-03-18 | Baylor College Of Medicine | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
| US20050059656A1 (en) * | 2003-04-07 | 2005-03-17 | Cornell Research Foundation, Inc. | Compositions and methods for protecting against mitochondria component-mediated pathology |
| WO2007056580A2 (en) * | 2005-11-08 | 2007-05-18 | Pharmadyn, Inc. | Methods and compositions for treating diseases associated with pathogenic proteins |
| EP1976495A2 (de) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Auf den serotonin-transporter wirkende verbindungen |
| CN101466380A (zh) | 2006-02-16 | 2009-06-24 | 麦克莱恩医院 | 治疗帕金森病的方法和组合物 |
| JP5665089B2 (ja) * | 2009-05-14 | 2015-02-04 | 国立大学法人岐阜大学 | プリオンタンパク質構造変換抑制剤及びその利用 |
| GB2568291A (en) * | 2017-11-13 | 2019-05-15 | Crisby Milita | New use |
| CN108143734A (zh) * | 2018-02-09 | 2018-06-12 | 南京中医药大学 | 阿莫地喹及其药学上可接受的盐在制备用于治疗阿尔茨海默病的药物中的应用 |
| EP3764102A4 (de) * | 2018-03-09 | 2021-12-15 | National University Corporation Tokyo Medical and Dental University | Nachweis von alzheimerkrankheit, frontotemporaler lobarer degeneration, amyotropher lateraler sklerose, parkinson-krankheit und demenz mit lewy-körpern, angezeigt durch marcks-phosphorylierung |
| WO2021257273A1 (en) * | 2020-06-15 | 2021-12-23 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| WO2023059867A1 (en) * | 2021-10-08 | 2023-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds for treating or preventing alzheimer's disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2546658A (en) * | 1949-07-23 | 1951-03-27 | Sterling Drug Inc | 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation |
| BE759163A (fr) * | 1969-11-20 | 1971-05-19 | Merck & Co Inc | (p-sulfonilyl)phenyluree appliquee au traitement de la maladie de mare |
| US3775403A (en) * | 1970-09-17 | 1973-11-27 | Merck & Co Inc | Diphenyl sulfones |
| US3702362A (en) * | 1970-09-17 | 1972-11-07 | Merck & Co Inc | Use of ureido diphenyl sulfones in the treatment of marek's disease |
| US3715375A (en) * | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
| US3786050A (en) * | 1971-07-06 | 1974-01-15 | Merck & Co Inc | Diphenyl sulfones |
| US3775444A (en) * | 1971-07-13 | 1973-11-27 | Merck & Co Inc | 4-amino,3-or 3'-fluoro-4'-ureido diphenyl sulfones |
| US4338334A (en) * | 1977-12-29 | 1982-07-06 | Merck & Co., Inc. | 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases |
| US4963565A (en) * | 1986-07-30 | 1990-10-16 | National Jewish Center For Immunology And Respiratory Medicine | In vivo treatment of mycobacterial infections with 6-cyclo octylamino-5,8-quinoline quinone |
| US5532219A (en) * | 1991-04-23 | 1996-07-02 | The University Of British Columbia | Dapsone and promin for the treatment of dementia |
| US6071493A (en) * | 1996-09-20 | 2000-06-06 | Baylor College Of Medicine | Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation |
| US6043283A (en) * | 1996-09-20 | 2000-03-28 | Baylor College Of Medicine | Tyramine compounds and their neuronal effects |
| US20020198231A1 (en) * | 1999-07-13 | 2002-12-26 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease |
| WO2001003649A2 (en) * | 1999-07-13 | 2001-01-18 | Alpha Research Group, Llc | Compositions and methods for the treatment of parkinson's disease |
| US20030092635A1 (en) * | 1999-12-08 | 2003-05-15 | Aberg A K Gunnar | Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease |
-
2004
- 2004-01-27 KR KR1020057013879A patent/KR20050119104A/ko not_active Ceased
- 2004-01-27 AT AT04705647T patent/ATE465408T1/de not_active IP Right Cessation
- 2004-01-27 AU AU2004207551A patent/AU2004207551B2/en not_active Ceased
- 2004-01-27 CA CA002514396A patent/CA2514396A1/en not_active Abandoned
- 2004-01-27 DE DE602004026683T patent/DE602004026683D1/de not_active Expired - Lifetime
- 2004-01-27 ZA ZA200506033A patent/ZA200506033B/xx unknown
- 2004-01-27 WO PCT/US2004/002236 patent/WO2004066943A2/en not_active Ceased
- 2004-01-27 ZA ZA200506000A patent/ZA200506000B/en unknown
- 2004-01-27 CN CNB2004800084618A patent/CN100502847C/zh not_active Expired - Fee Related
- 2004-01-27 CN CNA2004800083935A patent/CN101238370A/zh active Pending
- 2004-01-27 CA CA2514327A patent/CA2514327C/en not_active Expired - Fee Related
- 2004-01-27 AU AU2004207561A patent/AU2004207561B2/en not_active Ceased
- 2004-01-27 KR KR1020057013878A patent/KR20060002752A/ko not_active Ceased
- 2004-01-27 US US10/495,553 patent/US20060035929A1/en not_active Abandoned
- 2004-01-27 JP JP2006503068A patent/JP4571619B2/ja not_active Expired - Fee Related
- 2004-01-27 JP JP2006503038A patent/JP2006516629A/ja active Pending
- 2004-01-27 EP EP04705647A patent/EP1592388B1/de not_active Expired - Lifetime
- 2004-01-27 WO PCT/US2004/002147 patent/WO2004066940A2/en not_active Ceased
- 2004-01-27 EP EP04705636A patent/EP1594485A4/de not_active Withdrawn
-
2005
- 2005-07-26 IL IL169889A patent/IL169889A/en not_active IP Right Cessation
-
2007
- 2007-02-05 US US11/671,372 patent/US20070129439A1/en not_active Abandoned
-
2009
- 2009-03-10 AU AU2009200927A patent/AU2009200927A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004207551B2 (en) | 2008-12-11 |
| DE602004026683D1 (de) | 2010-06-02 |
| EP1592388A4 (de) | 2008-08-06 |
| AU2009200927A1 (en) | 2009-04-02 |
| WO2004066943A2 (en) | 2004-08-12 |
| KR20050119104A (ko) | 2005-12-20 |
| AU2004207551A1 (en) | 2004-08-12 |
| CA2514396A1 (en) | 2004-08-12 |
| KR20060002752A (ko) | 2006-01-09 |
| JP2006516629A (ja) | 2006-07-06 |
| EP1592388B1 (de) | 2010-04-21 |
| CA2514327A1 (en) | 2004-08-12 |
| JP2007524353A (ja) | 2007-08-30 |
| CN100502847C (zh) | 2009-06-24 |
| AU2004207561B2 (en) | 2009-07-30 |
| ZA200506033B (en) | 2007-01-31 |
| ZA200506000B (en) | 2007-11-28 |
| WO2004066940A3 (en) | 2005-01-20 |
| CN101238370A (zh) | 2008-08-06 |
| CA2514327C (en) | 2013-04-02 |
| JP4571619B2 (ja) | 2010-10-27 |
| WO2004066940A2 (en) | 2004-08-12 |
| IL169889A0 (en) | 2007-07-04 |
| IL169889A (en) | 2011-04-28 |
| WO2004066943A3 (en) | 2008-03-27 |
| AU2004207561A1 (en) | 2004-08-12 |
| EP1594485A4 (de) | 2009-01-14 |
| US20070129439A1 (en) | 2007-06-07 |
| CN1819822A (zh) | 2006-08-16 |
| EP1592388A2 (de) | 2005-11-09 |
| EP1594485A2 (de) | 2005-11-16 |
| US20060035929A1 (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60224383D1 (de) | Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen | |
| ATE526041T1 (de) | Verfahren zur hemmung okularer vorgänge | |
| WO2003042654A3 (en) | Multi-parameter high throughput screening assays (mphts) | |
| DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| DE602004016729D1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| ATE528410T1 (de) | Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration | |
| DE69926254D1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
| WO2006001877A3 (en) | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen | |
| DE602004026683D1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
| ATE422671T1 (de) | Verfahren zur diagnose von morbus alzheimer | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| ATE522230T1 (de) | Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit | |
| ATE352564T1 (de) | Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle | |
| DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| ATE378423T1 (de) | Polymorphismen des menschlichen hpxr gens und ihre anwendung in diagnose und therapie | |
| ATE495271T1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| ATE449964T1 (de) | DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN | |
| EP1363528A4 (de) | Verfahren zur diagnose und behandlung von herzerkrankungen | |
| WO2004005882A3 (en) | Multi-parameter high throughput screening assays (mphts) | |
| WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
| DE60004961D1 (de) | Analytisches Verfahren zur Beurteilung von nicht-humanen Tiermodellen für neurofibrilläre Degenerationserkrankungen | |
| DE602004024992D1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten | |
| ATE401576T1 (de) | Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen | |
| WO2003005034A3 (en) | Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene | |
| DE60225845D1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |